IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
7
Neutral
2
Bullish
5
Bearish
19
Neutral
2
Bullish
25
Bearish
12
Neutral
0
Bullish
20
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY16
Take Ltd (TAKE) is currently trading at 13.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Take Solutions is a global technology company focused on life sciences and support services, delivering domain‑intensive clinical, regulatory, safety and supply‑chain software and services with platforms such as OneClinical and the newly promoted Take.Health, serving biopharma innovators, generics manufacturers and enterprise clients across geographies with a product plus services model. FY26 represented a strong operational turnaround: consolidated total income rose 495.68% YoY to ₹6,087.26 Lakhs, consolidated net profit was ₹1,084.91 Lakhs and Q4 FY26 surged to ₹5,937.02 Lakhs, indicating rapid monetization of rebuilt operating streams and a concentrated quarter that materially changed annual results. Strategic emphasis is on AI‑driven healthcare and digital wellness: the company launched a Rs.5 crore Innovation Fund to back health and deep‑tech startups, and publicly prioritised Take.Health and analytics capabilities as growth enablers, signaling a shift toward productized and platform revenue alongside services. There is an important auditor qualification around income tax assets — standalone Rs.875.80 Lakhs and consolidated Rs.1,291.90 Lakhs — with contingent direct tax liabilities reported; this recurring qualification since FY2023 introduces uncertainty on recoverability and remains a material disclosure for stakeholders. Operationally the company used prior divestment proceeds to clear immediate statutory and debt obligations, incorporated TAKEVentures Private Limited in March 2026 to pursue strategic investments, and describes non‑cash M&A and partnership initiatives as active components of its growth plan, evidencing portfolio reshaping efforts.
Over the past 52 weeks, Take Ltd has traded between a low of ₹9.83 and a high of ₹49.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Take Ltd has a market capitalization of approximately 191.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Take Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 32.39 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 191.13 Cr, Take Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Take Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Take Ltd is 32.39. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Take Solutions share price is ₹29.20 as of 23 May, 2026.
Upcoming Result Date: Nov 13, 2026
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Take Solutions is a global technology company focused on life sciences and support services, delivering domain‑intensive clinical, regulatory, safety and supply‑chain software and services with platforms such as OneClinical and the newly promoted Take.Health, serving biopharma innovators, generics manufacturers and enterprise clients across geographies with a product plus services model.
FY26 represented a strong operational turnaround: consolidated total income rose 495.68% YoY to ₹6,087.26 Lakhs, consolidated net profit was ₹1,084.91 Lakhs and Q4 FY26 surged to ₹5,937.02 Lakhs, indicating rapid monetization of rebuilt operating streams and a concentrated quarter that materially changed annual results.
Strategic emphasis is on AI‑driven healthcare and digital wellness: the company launched a Rs.5 crore Innovation Fund to back health and deep‑tech startups, and publicly prioritised Take.Health and analytics capabilities as growth enablers, signaling a shift toward productized and platform revenue alongside services.
There is an important auditor qualification around income tax assets — standalone Rs.875.80 Lakhs and consolidated Rs.1,291.90 Lakhs — with contingent direct tax liabilities reported; this recurring qualification since FY2023 introduces uncertainty on recoverability and remains a material disclosure for stakeholders.
Operationally the company used prior divestment proceeds to clear immediate statutory and debt obligations, incorporated TAKEVentures Private Limited in March 2026 to pursue strategic investments, and describes non‑cash M&A and partnership initiatives as active components of its growth plan, evidencing portfolio reshaping efforts.
Healthcare Services
Healthcare Research, Analytics & Technology
192 Cr
Low Risk
32.6
59.5
-0.4
6.2
49.90
9.83
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
12.92 | 191 Cr | 32.39 | 6.17 | 0.00 | 13.73 | 15.37 | 35.38 | ||
67.02 | 191 Cr | -74.83 | 2.90 | 0.00 | 5.50 | 6.70 | 3.92 | ||
88.71 | 178 Cr | 22.24 | 2.32 | 0.00 | 1.60 | 4.43 | 4.80 | ||
75.31 | 177 Cr | 16.00 | 0.99 | 0.00 | 20.48 | 11.55 | 2.06 | ||
32.67 | 112 Cr | 24.10 | 1.87 | 0.00 | 7.75 | 8.97 | 6.14 | ||
17.00 | 25 Cr | 19.47 | 0.64 | 0.00 | 3.30 | 5.52 | 2.51 | ||
19.85 | 14 Cr | 128.36 | 0.67 | 0.00 | 0.51 | 1.31 | 0.17 | ||
| Median: 7 Co. | — | 32.67 | 177 Cr | 22.24 | 1.87 | 0.00 | 5.50 | 6.70 | 3.92 |
